Molecular Interaction of Serotonin 5-HT2A Receptor Residues Phe339(6.51) and Phe340(6.52) with Superpotent N-Benzyl Phenethylamine Agonists

Experiments were conducted to examine the molecular basis for the high affinity and potency of a new class of 5-HT2A receptor agonists, N-benzyl phenethylamines. Competition binding assays at several serotonin receptors confirmed that an N-arylmethyl substitution was necessary for affinity increases up to 300-fold over simple N-alkyl homologs, as well as enhanced selectivity for 5-HT2A versus 5-HT2C and 5-HT1A receptors. PI hydrolysis functional assays confirmed that these N-benzyl phenethylamines are potent and highly efficacious agonists at the rat 5-HT2A receptor. Virtual docking of these compounds into a human 5-HT2A receptor homology model indicated that the N-benzyl moiety might be interacting with Phe339(6.51), whereas the phenethylamine portion was likely to be interacting with Phe340(6.52). Experiments in h5-HT2A receptors with Phe339(6.51)L and Phe340(6.52)L mutations seem to support this hypothesis. Dramatic detrimental effects on affinity, potency, and intrinsic activity were observed with the Phe339(6.51)L mutation for all N-benzyl analogs, whereas most N-unsubstituted phenethylamines and traditional agonists were only weakly affected, if at all. Consistent with other published studies, the Phe340(6.52)L mutation detrimentally affected affinity, potency, and intrinsic activity of nearly all compounds tested, although a strong change in intrinsic activity was not seen with most N-aryl analogs. These data further validate the topology of our h5-HT2A receptor homology model. It is noteworthy that this study is the first to identify a hitherto unrecognized role for residue 6.51 in agonist activation of a serotonin G protein-coupled receptor (GPCR), whereas most previous reports have suggested a varied and sometimes contradictory role in homologous GPCRs.

[1]  H. Akil,et al.  Hydrophobic Residues of the D2 Dopamine Receptor Are Important for Binding and Signal Transduction , 1995, Journal of neurochemistry.

[2]  James J. Chambers,et al.  A homology-based model of the human 5-HT2A receptor derived from an in silico activated G-protein coupled receptor , 2002, J. Comput. Aided Mol. Des..

[3]  C. Strader,et al.  Identification of residues involved in ligand binding to the neurokinin-2 receptor. , 1995, Biochemistry.

[4]  M. Brann,et al.  Structure of a G-protein-coupling Domain of a Muscarinic Receptor Predicted by Random Saturation Mutagenesis (*) , 1996, The Journal of Biological Chemistry.

[5]  D. E. Nichols,et al.  Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats , 2002, Psychopharmacology.

[6]  R J Leatherbarrow,et al.  Structure-activity relationships in engineered proteins: analysis of use of binding energy by linear free energy relationships. , 1987, Biochemistry.

[7]  B. Roth,et al.  A single point mutation (Phe340-->Leu340) of a conserved phenylalanine abolishes 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptors. , 1993, Molecular pharmacology.

[8]  R. Glennon,et al.  Influence of amine substituents on 5-HT2A versus 5-HT2C binding of phenylalkyl- and indolylalkylamines. , 1994, Journal of medicinal chemistry.

[9]  J. Ballesteros,et al.  A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice. , 1998, Biochemistry.

[10]  B. Roth,et al.  Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptors. , 1997, Molecular pharmacology.

[11]  Michael R. Braden,et al.  C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor. , 2006, Journal of medicinal chemistry.

[12]  A. Shulgin,et al.  PIHKAL: A Chemical Love Story , 1991 .

[13]  R. Graham,et al.  Phe310 in Transmembrane VI of the α1B-Adrenergic Receptor Is a Key Switch Residue Involved in Activation and Catecholamine Ring Aromatic Bonding* , 1999, The Journal of Biological Chemistry.

[14]  J. Wess,et al.  Identification of a small intracellular region of the muscarinic m3 receptor as a determinant of selective coupling to PI turnover , 1989, FEBS letters.

[15]  E. Hulme,et al.  Alanine-scanning mutagenesis of transmembrane domain 6 of the M(1) muscarinic acetylcholine receptor suggests that Tyr381 plays key roles in receptor function. , 1999, Molecular pharmacology.

[16]  B. Roth,et al.  Differential ergoline and ergopeptine binding to 5-hydroxytryptamine2A receptors: ergolines require an aromatic residue at position 340 for high affinity binding. , 1995, Molecular pharmacology.

[17]  J. Wess,et al.  Delineation of muscarinic receptor domains conferring selectivity of coupling to guanine nucleotide-binding proteins and second messengers. , 1990, Molecular pharmacology.

[18]  H. Khorana,et al.  Mapping of the amino acids in membrane-embedded helices that interact with the retinal chromophore in bovine rhodopsin. , 1991, The Journal of biological chemistry.

[19]  Terrence P. Kenakin,et al.  A Pharmacologic Analysis of Drug-Receptor Interaction , 1987 .

[20]  J. Nardone,et al.  Delineation of a region in the B2 bradykinin receptor that is essential for high-affinity agonist binding. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  B. Roth,et al.  Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. , 2000, Molecular pharmacology.

[22]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[23]  R. Leurs,et al.  Mutational Analysis of the Antagonist-binding Site of the Histamine H1 Receptor* , 1999, The Journal of Biological Chemistry.

[24]  T. Gallaher,et al.  Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: identification of amino acids necessary for ligand binding and receptor activation. , 1993, Molecular pharmacology.

[25]  V. Watts,et al.  Serotonin 5-Hydroxytryptamine2A Receptor-Coupled Phospholipase C and Phospholipase A2 Signaling Pathways Have Different Receptor Reserves , 2003, Journal of Pharmacology and Experimental Therapeutics.

[26]  Michael R. Braden,et al.  1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. , 2006, Journal of medicinal chemistry.

[27]  Michael R. Braden,et al.  Differential phospholipase C activation by phenylalkylamine serotonin 5‐HT2A receptor agonists , 2005, Journal of neurochemistry.

[28]  C. Gillberg,et al.  Why Bother About Clumsiness? The Implications of Having Developmental Coordination Disorder (DCD) , 2003, Neural plasticity.

[29]  A. Ashkenazi,et al.  The Third Intracellular Loop of the 5‐Hydroxytryptamine2A Receptor Determines Effector Coupling Specificity , 1995, Journal of neurochemistry.

[30]  William L. Jorgensen,et al.  Aromatic-aromatic interactions: free energy profiles for the benzene dimer in water, chloroform, and liquid benzene , 1990 .

[31]  H. Zhong,et al.  Inducible expression of beta 1- and beta 2-adrenergic receptors in rat C6 glioma cells: functional interactions between closely related subtypes. , 1996, Molecular pharmacology.

[32]  J. Nakai,et al.  Location of a region of the muscarinic acetylcholine receptor involved in selective effector coupling , 1988, FEBS letters.

[33]  B. Roth,et al.  A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism. , 2000, The Journal of pharmacology and experimental therapeutics.

[34]  M. Kietzmann Pharmacological analysis of drug-receptor interaction: Kenakin, T., 2nd Edn, XII + 483 pp. New York: Raven Press (1993) , 1994 .

[35]  K. Minneman,et al.  Inducible expression of alpha 1B-adrenoceptors in DDT1 MF-2 cells: comparison of receptor density and response. , 1995, European journal of pharmacology.

[36]  J. Chambers,et al.  Translocation of the 5-alkoxy substituent of 2,5-dialkoxyarylalkylamines to the 6-position: effects on 5-HT(2A/2C) receptor affinity. , 2002, Bioorganic & medicinal chemistry letters.